/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Harmony Biosciences Holdings (HRMY) generated about $960 million in revenue and $181 million in net income (a 18.9% net margin) over the trailing twelve months, growing at roughly 40.3% a year. Figures are from SEC filings; this is analysis, not investment advice.
Harmony Biosciences Holdings generated about $960 million in revenue over the trailing twelve months. Revenue has grown at roughly 40.3% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Yes, Harmony Biosciences Holdings reported about $181 million in net income over the trailing twelve months, a net profit margin of roughly 18.9%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Harmony Biosciences Holdings runs a gross margin of about 75.4%, an operating margin of about 24.0%, a net margin of about 18.9%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Harmony Biosciences Holdings's revenue has compounded at roughly 40.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside HRMY's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.
Fiscal year ends Dec.